Chlamydia trachomatis (20-50%), Mycoplasma genitalium (10-25%), or adenovirus, Trichomonas vaginalis, herpes simplex virus (<10%).
A pathogen is often not identifiable (30-60%). Testing for Ureaplasma species is not recommended.
|Incubation period||Depending on the organism|
|How far back to trace isolated||See relevant sections if C. trachomatis or M. genitalium are isolated|
|Usual testing method||C. trachomatis and M. genitalium nucleic acid amplification testing (NAAT) Consider NAAT testing for adenovirus, T. vaginalis or herpes simplex virus if clinically indicated.|
|Common symptoms||Dysuria, urethral discharge|
|Likelihood of transmission per act of unprotected intercourse||Depends on specific pathogen|
|Likelihood of long-term sexual partner being infected||Depends on specific pathogen|
|Protective effect of condoms||High for sexually transmitted pathogens|
|Transmission by oral sex||May be relevant for C. trachomatis|
|Duration of potential infectivity||Depends on specific pathogen|
|Important sequelae||If untreated, may lead to epididymo-orchitis or infection of female sexual partner(s) with increased risk for pelvic inflammatory disease|
|Direct benefit of detection and treatment of contacts||Cure where a treatable pathogen is found|
|Usual management of contacts||Counselling, clinical examination, test for C. trachomatis and M. genitalium if index patient is positive. Consider presumptively treating sexual contacts — see national STI guidelines|
|Contact tracing priority||High — Where C. trachomatis or M. genitalium is detected in the index patient|
C. trachomatis is notifiable (Trichomoniasis is notifiable in Northern Territory)